Schrodinger Inc Dossier
Qualitative Analysis
Business overview
Schrödinger, Inc. (NASDAQ: SDGR) is a leading scientific software and biotechnology company that operates a physics-based computational platform designed to accelerate molecular discovery. The company operates in two primary segments: Software and Drug Discovery. The Software segment licenses its advanced computational platform to biopharmaceutical, materials science, and industrial companies, as well as academic institutions globally. The Drug Discovery segment leverages this platform to advance a diverse portfolio of preclinical and clinical programs, both internally and through strategic collaborations with major pharmaceutical companies.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Accelerating the transition of software customers from on-premise multiyear licenses to hosted software contracts, targeting approximately 75% hosted adoption within three years and substantial completion by 2028.
Expected impact: Improves long-term revenue predictability and scalability, aligning recognized revenue closer to Annual Contract Value (ACV), despite near-term accounting headwinds to recognized software revenue.
Developing and launching Bunsen, an LLM-built agentic AI co-scientist designed to autonomously execute complex molecular discovery workflows and automate the Design-Predict-Make-Test-Analyze (DPMTA) cycle.
Expected impact: Democratizes platform access to a broader user base, increases computational throughput, and drives incremental revenue via throughput-based licensing.
Expanding the computational platform's capabilities to predict toxicology risks early in drug discovery, utilizing structurally enabled off-targets to identify unknown liabilities and mitigate them via SAR panels.
Expected impact: Reduces late-stage clinical failures and animal testing for customers, expanding the platform's addressable market and utility.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Integrates Lilly's TuneLab federated learning models into Schrödinger's LiveDesign enterprise informatics platform, combining physics-based simulations with machine learning to solve data scarcity in drug discovery.
Terms: Not disclosed.
Grants Manas AI ultra-large-scale access to Schrödinger's computational platform, integrating physics-based modeling with Manas AI's algorithms to improve predictive accuracy and speed.
Terms: Not explicitly disclosed.
Substantially increases Novartis's access to Schrödinger's computational platform to industry-leading scale while collaborating on multiple drug discovery targets.
Terms: Includes a $150 million upfront payment (received in Q1 2025) and up to $2.3 billion in potential milestone payments plus royalties.